Johnson & Johnson

JNJ · NYSE · Pharmaceuticals
Close · 2026-11-17
As of 2026-11-18PDF

Fair value · base case

Range –
Above our whole range

Johnson & Johnson trades above base-case fair value as legal and pricing risks weigh.

Price vs. our range

Bear $116Base $173Bull $263Price $278.70
Market cap
P/E
FY2026 diluted EPS
FCF yield
Free cash flow divided by market cap
Net debt
Cash, investments and debt

What matters

Select an underlined figure or citation to see its source.

Price exceeds base case

At , the stock trades above the base-case fair value of .

Market implies aggressive growth

The current price implies five-year revenue growth of , far above the historical anchor of .

Net debt widened sharply

Net debt widened sharply as net cash moved to from after acquisition borrowing .

Legal and pricing risks remain

Large lawsuit settlements and reimbursement cuts may lower cash flows and raise uncertainty, reducing fair value .
293 reported figures6 assumptionsConfidence Medium

Business and products

Johnson & Johnson sells medical products to wholesalers, hospitals, doctors, and eye care professionals . Competition, research, patents, and regulation drive the business .

  • Innovative Medicine sells prescription medicines for cancer, immune, nerve, heart, and infectious diseases to wholesalers, hospitals, and doctors .
  • MedTech sells cardiovascular, orthopaedic, surgery, and vision products to hospitals, wholesalers, retailers, and eye care professionals .
Show allShow less
  • Competition and the need for new products and protected intellectual property require substantial research investment .
  • Government regulation affects product approval, manufacturing, advertising, labeling, and safety reporting .
  • Patent challenges and biosimilar launches can reduce sales of key medicines .

Valuation ranges

Each bar shows the range a method supports.

Supported rangePriceBase case
$150$200$250$300Price $278.70DCFBear to bull$116$263Closing pricesPrice history$199.58$285.75

· of explicit projections

How we got the discount rate

Risk-free rate · Live Treasury
Beta
Equity risk premium
WACC

How sensitive is it?

Fair value per share under different discount rates and long-run growth.

Rate ↓ Growth →2.0%2.5%3.0%3.5%4.0%8.0%$174$187$203$223$2488.4%$162$173$187$204$2248.8%$151$161$173$187$2049.2%$142$151$161$173$1879.6%$133$141$150$160$172
Below priceAbove priceOutlined = current case

Build your own view

Adjust the assumptions to see how they change fair value.

Base case: Base pairs growth near the revenue anchor with a steady margin delta around normalized cash flow .
Five-year revenue CAGR
Historical growth anchor
Starts from and reaches the target in year five.
Higher = you demand more return for the risk
Projection horizon
Your fair value
$173
38% below the close of
What the market is betting on

The closing price implies 15.2% revenue growth next year.

Show the math
Starting cash flow
Year-five cash-flow margin23.26%
Present value of 15 years of cash flow$242.41B
Present value of cash flow after year 15$201.83B
Net debt
Shares outstanding
Fair value per share$173

Financial history

Annual figures from SEC filings.

Revenue

FY2026
FY2022FY2026

Operating margin

FY2026
FY2022FY2026

Free cash flow (levered, simple)

FY2026
FY2022FY2026

Diluted EPS

FY2026
FY2022FY2026

The numbers

Select a figure to see where it came from.

Net debt
MetricFY2022FY2023FY2024FY2025FY2026
Revenue
Operating income
Net income
R&D
Operating cash flow
Capital expenditure
Share repurchases
Free cash flow

Key risks

Ranked by impact on fair value. Tap to expand.

HighLitigation could materially reduce fair value.
Talc and other lawsuits could bring large settlements, fines and reputational harm. That may cut cash flows and raise uncertainty, lowering fair value .
HighPricing pressure could erode revenue.
Government and insurer reimbursement cuts may lower product prices and sales. That could shrink margins and cash flow, reducing fair value .
HighProduct safety concerns could hurt sales.
Recalls, safety alerts and lawsuits can cut sales, raise costs and damage trust. Those effects may lower future cash flows and fair value .
ElevatedCompetition could pressure prices and growth.
Rivals may launch better or cheaper products and win key rights. That can slow sales and raise acquisition costs, hurting fair value .
ElevatedSupply disruptions could reduce sales.
Manufacturing delays or supplier failures can cause shortages and lost sales. Remediation costs and reputational harm could lower fair value .
ElevatedIP challenges could curb long-term growth.
Weaker patent rights and costly disputes may limit product protection. That can reduce expected cash flows and fair value .

Where this comes from

Numbers are calculated by code from these sources. The AI writes explanations only.

Source
JOHNSON & JOHNSON Form 10-K filed 2026-02-11
Accession
0000200406-26-000016
Open source ↗
Source
Yahoo Finance (JNJ) — development-only price feed; not for redistribution
Locator
2026-11-17
Open source ↗
Source
U.S. Treasury Daily Par Yield Curve Rates
Locator
2026-11-17, 10 Yr
Open source ↗
Source
Aswath Damodaran, NYU Stern — Monthly U.S. implied equity risk premiums (2026-11-01)
Locator
Historical ERP / ERP (T12 m with sustainable payout)
Open source ↗
Source
Aswath Damodaran, NYU Stern — Monthly U.S. implied equity risk premiums (2026-11-01)
Locator
Historical ERP / T.Bond Rate
Open source ↗
Source
Aswath Damodaran, NYU Stern — U.S. industry betas (2026-01-05)
Locator
Industry Averages / Drugs (Pharmaceutical) / Unlevered beta corrected for cash
Open source ↗

What this report checked

Standard report

Company lookupDone
Annual filingDone
Filing figuresDone
Filing textDone
Market priceDone
Price historyDone
Treasury yieldDone
Equity risk premiumDone
Industry betaDone
Peer multiplesSkipped
Business and productsDone
Risk factorsDone
Financial qualityDone
Valuation assumptionsDone
ValuationDone
Report synthesisDone